Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks - Yahoo Finance

1. Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks  Yahoo Finance
2. Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company  Investors | Eli Lilly and Company
3. Amid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod  FiercePharma
4. Weight-Loss Drug Zepbound Offers a New Way to Treat Sleep Apnea  The New York Times